Immunotherapy, particularly with ICIs, has demonstrated enhanced clinical efficacy in solid tumors characterized by a high tumor mutational burden.[21] Our research findings similarly reveal that PD-1 inhibitors in combination with chemotherapy significantly improved the OS in MSI-H patients, with a notable difference between groups (P < .01). This evidence concerns the gene PDCD1 and neoplasm.